Oruka Therapeutics, Inc. (ORKA) News
Track canonical SquawkNews coverage tagged to ORKA, Oruka Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 17 indexed stories across 11 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Oruka Therapeutics Price Target Maintained With a $165.00/Share by Wedbush
Ratings actions from Benzinga
NEWS | Sep 24, 2026, 12:51 PM UTC
L
Oruka Therapeutics Price Target Maintained With a $120.00/Share by HC Wainwright & Co.
Ratings actions from Benzinga
NEWS | Sep 24, 2026, 11:42 AM UTC
L
Oruka Therapeutics, Inc. (ORKA) Week 28 Psoriasis Data: PASI 100 71.4%
Oruka Therapeutics reported EVERLAST-A Week 28 data for ORKA-001: PASI 100 rose to 71.4% and PASI 90 to 87.3% without dosing after Week 4; safety remained consistent with IL-23 class. Placebo crossovers showed similar re
NEWS | Sep 23, 2026, 11:02 AM UTC
L
Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing
PASI 100 increased to 71.4% and PASI 90 increased to 87.3%, despite no dosing after Week 4Placebo crossover patients reached PASI 100 and PASI 90 rates similar to those initially dosed with ORKA-001ORKA-001 maintained a
NEWS | Sep 23, 2026, 11:02 AM UTC
L
ORKA - Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing
ORKA - Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing
NEWS | Sep 23, 2026, 11:00 AM UTC
L
Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference
MENLO PARK, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) NASDAQ:ORKA, a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of
EQUITY | Sep 09, 2026, 08:03 PM UTC
L
ORKA - Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference
ORKA - Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference
EQUITY | Sep 09, 2026, 08:01 PM UTC
L
HC Wainwright maintains $120 price target for Oruka Therapeutics
HC Wainwright & Co. maintained its $120.00/share price target on Oruka Therapeutics, according to Benzinga ratings actions.
EQUITY | Sep 03, 2026, 10:27 AM UTC
L
Oruka Therapeutics appoints Todd Edwards as chief commercial officer
Oruka Therapeutics appoints Todd Edwards as chief commercial officer.
MNA | Aug 24, 2026, 08:01 PM UTC
H
Oruka Therapeutics may offer up to $1B of securities
Oruka Therapeutics files with the SEC that it may offer up to $1B of securities, according to Hammerstone MarketTalk.
REGULATION | Aug 21, 2026, 08:20 PM UTC
L
Oruka Therapeutics Insider Sold Shares Worth $846,180, According to a Recent SEC Filing
() -- Arjun Agarwal, Senior Vice President, Finance, on July 13, 2026, sold 9,999 shares in Oruka Therapeutics (ORKA) for $846,180. Following the Form 4 filing with the SEC, Agarwal has control over a total of 15,312 com
GEOPOLITICS | Jul 13, 2026, 09:22 PM UTC
L
Oruka Therapeutics sharers are trading lower after a SEC filing disclosed that Fairmount Healthcare Fund II sold shares worth about $300 mil
Oruka Therapeutics sharers are trading lower after a SEC filing disclosed that Fairmount Healthcare Fund II sold shares worth about $300 million.
REGULATION | Jul 02, 2026, 03:42 PM UTC
L
Oruka Therapeutics Shares Drop After Hours After Fairmount Unloads 3.55 Million Shares
Oruka Therapeutics Inc. (NASDAQ: ORKA ) shares fell in after-hours trading on Wednesday after SEC filings showed major shareholder Fairmount Healthcare Fund II sold a large block of shares worth about $300 million. ORKA
REGULATION | Jul 02, 2026, 06:30 AM UTC
L
UBS Maintains Buy on Oruka Therapeutics, Raises Price Target to $130
UBS analyst Michael Yee maintains Oruka Therapeutics (NASDAQ: ORKA ) with a Buy and raises the price target from $100 to $130.
EQUITY | Jul 01, 2026, 04:13 PM UTC
M
ORKA: HC Wainwright Reiterates Buy
HC Wainwright & Co. reiterates buy rating on Oruka Therapeutics and maintains $120 price target
EQUITY | Jun 23, 2026, 10:52 AM UTC
H
DFTX +65% on Phase 3 Results
DFTX shares rise 65% on positive topline results from Phase 3 Emerge Study of DT120
EQUITY | Jun 22, 2026, 01:17 PM UTC
H
APGE +45% on Acquisition
AbbVie to acquire Apogee Therapeutics, sending APGE stock up 45% premarket
EQUITY | Jun 22, 2026, 12:21 PM UTC